Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression by Weijuan Zhang, Jiejie Xu, Hailong Liu, Yu Zhu, Zewei Wang, Han Zeng, Zhaopei Liu, Yuan Chang, Le Xu, Kaifeng Jin, Jingtong Xu, Xiaohe Su, Yawei Ding, Lingkai Zhang, Jiaxing Sun, Yuzhen Wu

“…Background The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of TP53 pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). …”
Get full text